The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion

Table 3 Comparison of chemotherapy response in TNBC and non-TNBC patients overexpressing or not BRCA1-IRIS

Clinical response	CR	SD	PD	χ2	p-value	Total
IRIS⁺ TNBC Non-TNBC	12 4 8	2 0 2	29 24 5	9.575	0.0020	43
IRIS⁻ TNBC Non-TNBC	39 6 33	5 0 3	11 7 4	10.521	0.0052	53
Total	51	5	40			96

χ2 is Chi Square test, Abbreviations: TNBC triple negative breast cancer, CR complete response, SD stable disease, PD progressive disease

ISSN: 1471-2407